HCA Healthcare, Inc. (NYSE:HCA) Shares Bought by Transcend Capital Advisors LLC

Transcend Capital Advisors LLC grew its stake in shares of HCA Healthcare, Inc. (NYSE:HCA) by 4.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,187 shares of the company’s stock after acquiring an additional 54 shares during the quarter. Transcend Capital Advisors LLC’s holdings in HCA Healthcare were worth $321,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Kinetic Partners Management LP purchased a new position in shares of HCA Healthcare in the 3rd quarter worth $50,524,000. EP Wealth Advisors LLC raised its holdings in HCA Healthcare by 501.8% in the third quarter. EP Wealth Advisors LLC now owns 208,965 shares of the company’s stock valued at $51,401,000 after buying an additional 174,240 shares during the period. Canada Pension Plan Investment Board raised its stake in shares of HCA Healthcare by 51.6% in the 3rd quarter. Canada Pension Plan Investment Board now owns 355,730 shares of the company’s stock valued at $87,502,000 after acquiring an additional 121,100 shares during the period. Mitsubishi UFJ Trust & Banking Corp raised its position in HCA Healthcare by 83.4% in the third quarter. Mitsubishi UFJ Trust & Banking Corp now owns 254,408 shares of the company’s stock valued at $62,579,000 after purchasing an additional 115,720 shares during the period. Finally, Avidity Partners Management LP purchased a new stake in shares of HCA Healthcare during the 3rd quarter valued at about $28,239,000. Institutional investors and hedge funds own 62.73% of the company’s stock.

HCA Healthcare Stock Performance

HCA opened at $311.42 on Tuesday. The business has a fifty day simple moving average of $323.67 and a 200-day simple moving average of $295.56. The firm has a market cap of $82.36 billion, a PE ratio of 15.52, a P/E/G ratio of 1.48 and a beta of 1.65. The company has a quick ratio of 1.02, a current ratio of 1.16 and a debt-to-equity ratio of 29.26. HCA Healthcare, Inc. has a fifty-two week low of $215.96 and a fifty-two week high of $335.83.

HCA Healthcare (NYSE:HCA) last posted its quarterly earnings data on Friday, April 26th. The company reported $5.36 EPS for the quarter, beating analysts’ consensus estimates of $5.01 by $0.35. The company had revenue of $17.34 billion during the quarter, compared to analyst estimates of $16.81 billion. HCA Healthcare had a net margin of 8.20% and a return on equity of 674.49%. The business’s quarterly revenue was up 11.2% on a year-over-year basis. During the same period in the prior year, the firm earned $4.93 earnings per share. As a group, equities analysts predict that HCA Healthcare, Inc. will post 20.58 EPS for the current fiscal year.

HCA Healthcare announced that its board has initiated a stock repurchase program on Tuesday, January 30th that authorizes the company to repurchase $6.00 billion in outstanding shares. This repurchase authorization authorizes the company to purchase up to 7.4% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s board of directors believes its stock is undervalued.

HCA Healthcare Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 28th. Investors of record on Friday, June 14th will be issued a dividend of $0.66 per share. This represents a $2.64 annualized dividend and a dividend yield of 0.85%. The ex-dividend date is Friday, June 14th. HCA Healthcare’s dividend payout ratio is currently 13.16%.

Insider Buying and Selling at HCA Healthcare

In other news, SVP Kathryn A. Torres sold 3,861 shares of the company’s stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $307.00, for a total value of $1,185,327.00. Following the transaction, the senior vice president now directly owns 15,899 shares of the company’s stock, valued at $4,880,993. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other HCA Healthcare news, EVP Michael S. Cuffe sold 3,200 shares of the company’s stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $306.79, for a total transaction of $981,728.00. Following the completion of the sale, the executive vice president now directly owns 24,929 shares in the company, valued at $7,647,967.91. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Kathryn A. Torres sold 3,861 shares of the firm’s stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $307.00, for a total value of $1,185,327.00. Following the completion of the sale, the senior vice president now directly owns 15,899 shares in the company, valued at approximately $4,880,993. The disclosure for this sale can be found here. In the last quarter, insiders have sold 14,840 shares of company stock worth $4,588,869. 1.70% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on HCA shares. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $335.00 target price on shares of HCA Healthcare in a research report on Wednesday, April 10th. Truist Financial upped their price target on shares of HCA Healthcare from $320.00 to $345.00 and gave the company a “buy” rating in a report on Wednesday, January 31st. Sanford C. Bernstein lowered HCA Healthcare from an “outperform” rating to a “market perform” rating and boosted their price objective for the company from $277.00 to $301.00 in a research report on Thursday, January 4th. Barclays upped their price target on shares of HCA Healthcare from $356.00 to $367.00 and gave the stock an “overweight” rating in a research report on Monday. Finally, Wells Fargo & Company raised their target price on HCA Healthcare from $303.00 to $315.00 and gave the company an “equal weight” rating in a research report on Thursday, March 28th. Four equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $313.88.

About HCA Healthcare

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.